Dr. HC reports grants from CIHR, other from Alberta Prion Research Institute, other from Alzheimer’s Research UK, other from Alzheimer Society of Canada, other from Canadian Nurses Foundation, non-financial support from Fonds de recherche du Québec – Santé, other from Michael Smith Foundation for Health Research, other from New Brunswick Health Research Foundation, other from Nova Scotia Health Research Foundation, non-financial support from Ontario Brain Institute, non-financial support from Pfizer Inc., other from Robin and Barry Picov Family Foundation, other from Sanofi, other from Saskatchewan Health Research Foundation, and other from Women’s Brain Health Initiative, during the conduct of the study. Ms. S Best, Mr. SD, Dr. JF, Dr. JR, Mr. JL, Mr. ZM, Ms. RP, and Mr. VW have nothing to disclose. Drs. RC, RD, AE, SG, DH, IM, EM, KM, NP, JP, KR, and MCT report grants from CIHR, during the conduct of the study. Dr. MA reports grants from CHIR, during the conduct of the study; reports grants from GSK, grants from Pfizer, and grants from Sanofi, outside the submitted work. Dr. SEB reports funding to the institution from CIHR for the Compass-ND study, and personal fees from Novartis, Merck, Pfizer, Eli Lilly, Biogen/Medscape, and grants to the institution from Novartis, Eli Lilly, GE Healthcare, Biogen Idec, Genentech, Optina, outside of submitted work. Dr. MB reports grants from CIHR, during the conduct of the study; grants from Ontario Brain Institute/ONDRI study, outside the submitted work. Dr. S Duchesne reports grants from CHIR, during the conduct of the study; reports other from True Positive Medical Devices Inc., from Montreal, Canada, outside the submitted work. Dr. HF reports grants from CIHR, Brain Canada, National Institutes of Health: Alzheimer Disease Cooperative Study U19AG10483-26, Biohaven Pharmaceuticals, Toyama Pharmaceuticals, and development grant funding from Probiodrug, during the conduct of the study; service agreements with Eisai Pharmaceuticals, Genentech/Roche Pha, maceuticals, Banner Health Institute, Samus Therapeutics, Merck Pharmaceuticals, Tau RX, Arkuda Therapeutics, and Samumed; speaker fees from World Events Forum, Medscape, Optum, and San Diego Academy of Family Physicians; travel expenses from Axon Neurosciences, Alion Pharmaceuticals, Probiodrug, and Dominantly Inherited Alzheimer’s Disease. Dr. G-YR Hsiung reports grants from CHIR, during the conduct of the study; reports grants from CIHR and NIH, professorship support from Alzheimer Society of BC, clinical trials investigator support from AstraZeneca, Eli Lilly, and Roche/Genentech, outside the submitted work. Dr. MM reports grants from CIHR, during the conduct of the study; other from Associate Editor, Current Pharmacogenomics and Personalized Medicine, personal fees from Bioscape Medical Imaging CRO, personal fees from GE Healthcare, personal fees from UCB, grants from CIHR, grants from Early Researcher Award, Ministry of Economic Development and Innovation of Ontario, grants from Ontario Brain Institute, grants from Sunnybrook AFP Innovation Fund, grants from Alzheimer’s Drug Discovery Foundation (ADDF), grants from Brain Canada, grants from Heart and Stroke Foundation Centre for Stroke Recovery, grants from Weston Brain Institute, personal fees from Novartis, personal fees from Henry Stewart Talks, other from Novartis, grants from Roche, grants from Washington University, grants from Teva, and other from Teva, outside the submitted work. Dr. EES reports grants from CIHR, during the conduct of the study; and grants from CIHR and grants from Brain Canada, outside the submitted work. Dr. KR reports being founder and president of DGI Clinical, which during the initial study period had contracts on individualized outcome assessment with Roche, Otsuka, and Lundbeck.
Alzheimer Society of Canada. Rising tide: the impact of dementia on Canadian society. Toronto: Alzheimer Society of Canada; 2010.
Gorelick, PB, Scuteri, A, Black, SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–713.10.1161/STR.0b013e3182299496
Iadecola, C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844–66.10.1016/j.neuron.2013.10.008
Schneider, JA, Boyle, PA, Arvanitakis, Z, Bienias, JL, Bennett, DA. Subcortical infarcts, Alzheimer’s disease pathology, and memory function in older persons. Ann Neurol. 2007;62(1):59–66.10.1002/ana.21142
Snowden, JS, Neary, D, Mann, DM. Frontotemporal dementia. Br J Psychiatry. 2002;180:140–3.10.1192/bjp.180.2.140
Kertesz, A. Frontotemporal dementia/Pick’s disease. Arch Neurol. 2004;61(6):969–71.10.1001/archneur.61.6.969
Hogan, DB, Fiest, KM, Roberts, JI, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S83–95.10.1017/cjn.2016.2
Petersen, RC, Negash, S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13(1):45–53.10.1017/S1092852900016151
Morris, JC, Mild cognitive impairment is early-stage Alzheimer disease. Arch Neurol. 2006;63:15–16.10.1001/archneur.63.1.15
Sachdev, PS, Lipnicki, DM, Crawford, J, et al. Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study. PLoS One. 2013;8(3):e59649.10.1371/journal.pone.0059649
Reisberg, B, Gauthier, S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer’s disease. Int Psychogeriatr. 2008;20(1):1–16.10.1017/S1041610207006412
Jessen, F, Wolfsgruber, S, Wiese, B, et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement. 2014;10(1):76–83.10.1016/j.jalz.2012.09.017
Das, S, Zijdenbos, AP, Harlap, J, Vins, D, Evans, AC. LORIS: a web-based data management system for multi-center studies. Front Neuroinform. 2011;5:37.
Raina, PS, Wolfson, C, Kirkland, SA, et al. The Canadian longitudinal study on aging (CLSA). Can J Aging. 2009;28(3):221–9.10.1017/S0714980809990055
Weiner, MW, Veitch, DP, Aisen, PS, et al. Impact of the Alzheimer’s disease neuroimaging initiative, 2004 to 2014. Alzheimers Dement. 2015;11(7):865–84.10.1016/j.jalz.2015.04.005
Shatenstein, B, Nadon, S, Godin, C, Ferland, G. Development and validation of a food frequency questionnaire. Can J Diet Pract Res. 2005;66(2):67–75.10.3148/66.2.2005.67
Montero-Odasso, M, Pieruccini-Faria, F, Bartha, R, et al. Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). J Alzheimers Dis. 2017;59(2): 707–21.10.3233/JAD-170149
Schneider, JA, Arvanitakis, Z, Leurgans, SE, Bennett, DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200–8.10.1002/ana.21706
Iturria-Medina, Y, Hachinski, V, Evans, AC. The vascular facet of late-onset Alzheimer’s disease: an essential factor in a complex multifactorial disorder. Curr Opin Neurol. 2017;30(6):623–9.10.1097/WCO.0000000000000497
Smith, EE, Beaudin, AE. New insights into cerebral small vessel disease and vascular cognitive impairment from MRI. Curr Opin Neurol. 2018;31(1):36–43.10.1097/WCO.0000000000000513
Nestor, SM, Misic, B, Ramirez, J, et al. Small vessel disease is linked to disrupted structural network covariance in Alzheimer’s disease. Alzheimers Dement. 2017;13(7):749–60.10.1016/j.jalz.2016.12.007
Marian, V, Blumenfeld, HK, Kaushanskaya, M, The Language Experience and Proficiency Questionnaire (LEAP-Q): assessing language profiles in bilinguals and multilinguals. J Speech Lang Hear Res. 2007;50(4):940–67.10.1044/1092-4388(2007/067)
Wechsler, D. Wechsler memory scale - revised. San Antonio: The Psychological Corporation; 1987.
Morris, JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.10.1212/WNL.43.11.2412-a
Welsh, KA, Butters, N, Mohs, RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994;44(4):609–14.10.1212/WNL.44.4.609
Nasreddine, ZS, Phillips, NA, Bedirian, V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.10.1111/j.1532-5415.2005.53221.x
Lawton, M, Brody, EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–196.10.1093/geront/9.3_Part_1.179
Possin, KL, Laluz, VR, Alcantar, OZ, Miller, BL, Kramer, JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer’s disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011; 49(1):43–8.10.1016/j.neuropsychologia.2010.10.026
Folstein, MF, Folstein, SE, McHugh, PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.10.1016/0022-3956(75)90026-6
FTLD Working Group of the ADC program. NACC Uniform Data Set (UDS)-FTLD Module Version 3.0. Seattle, WA: University of Washington; 2015.
Cummings, JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–6.10.1212/WNL.48.5_Suppl_6.10S
Jenkinson, C, Fitzpatrick, R, Peto, V, Greenhall, R, Hyman, N. The Parkinson’s disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26(5):353–7.10.1093/ageing/26.5.353
Goetz, CG, Fahn, S, Martinez-Martin, P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41–7.10.1002/mds.21198
Hachinski, VC, Iliff, LD, Zilhka, E, Cerebral blood flow in dementia. Arch Neurol. 1975;32(9):632–7.10.1001/archneur.1975.00490510088009
Belleville, S, Fouquet, C, Duchesne, S, Collins, DL, Hudon, C. Detecting early preclinical Alzheimer’s disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing. J Alzheimers Dis. 2014;42:S375–82.10.3233/JAD-141470
Stuss, DT. The Ontario Brain Institute: completing the circle. Can J Neurol Sci. 2014;41(6):683–93.
Hallam, BJ, Jacova, C, Hsiung, GY, et al. Early neuropsychological characteristics of progranulin mutation carriers. J Int Neuropsychol Soc. 2014;20(7):694–703.10.1017/S1355617714000551
de Frias, CM, Dixon, RA, Camicioli, R. Neurocognitive speed and inconsistency in Parkinson’s disease with and without incipient dementia: an 18-month prospective cohort study. J Int Neuropsychol Soc. 2012;18(4):764–72.10.1017/S1355617712000422
O’Bryant, SE, Xiao, G, Barber, R, et al. A blood-based screening tool for Alzheimer’s disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011;6(12):e28092.10.1371/journal.pone.0028092
Agarwal, R, Tripathi, CB. Diagnostic utility of CSF Tau and Abeta(42) in dementia: a meta-analysis. Int J Alzheimers Dis. 2011;2011:503293.
Pekeles, H, Qureshi, HY, et al. Development and validation of a salivary tau biomarker in Alzheimer disease. Alzheimers Dement. 2019;11:53–60.
Vellas, B, Hampel, H, Rougé-Bugat, ME, et al. Alzheimer’s disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging. 2012;16(4):339–45.10.1007/s12603-012-0044-x
Duchesne, S, Valdivia, F, Robitaille, N et al. Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. Alzheimers Dement. 2015;11(2):161–74.
Anandh, KR, Sujatha, CM, Ramakrishnan, S. A method to differentiate mild cognitive impairment and Alzheimer in MR images using Eigen value descriptors. J Med Syst. 2016;40(1):25.
Wardlaw, JM, Smith, EE, Biessels, GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.10.1016/S1474-4422(13)70124-8
Fazekas, F, Kleinert, R, Offenbacher, H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683–9.10.1212/WNL.43.9.1683
Hardy, J, Orr, H. The genetics of neurodegenerative diseases. J Neurochem. 2006;97(6):1690–9.10.1111/j.1471-4159.2006.03979.x
Caracciolo, B, Xu, W, Collins, S, Fratiglioni, L. Cognitive decline, dietary factors and gut-brain interactions. Mech Ageing Dev. 2015;136–137:59–69.
Hill, JM, Clement, C, Pogue, AI, Bhattacharjee, S, Zhao, Y, Lukiw, WJ. Pathogenic microbes, the microbiome, and Alzheimer’s disease (AD). Front Aging Neurosci. 2014;6:127.
Bhattacharjee, S, Lukiw, WJ. Alzheimer’s disease and the microbiome. Front Cell Neurosci. 2013;7:153.
Mayer, EA, Knight, R, Mazmanian, SK, Cryan, JF, Tillisch, K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34(46):15490–6.10.1523/JNEUROSCI.3299-14.2014
Zapata, HJ, Quagliarello, VJ. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc. 2015;63(4):776–81.10.1111/jgs.13310
Hill, JM, Bhattacharjee, S, Pogue, AI, Lukiw, WJ. The gastrointestinal tract microbiome and potential link to Alzheimer’s disease. Front Neurol. 2014;5:43.10.3389/fneur.2014.00043
Tremlett, H, Bauer, KC, Appel-Cresswell, S, Finlay, BB, Waubant, E. The gut microbiome in human neurological disease: a review. Ann Neurol. 2017;81(3):369–82.
Mather, KA, Kwok, JB, Armstrong, N, Sachdev, PS. The role of epigenetics in cognitive ageing. Int J Geriatr Psychiatry. 2014;29(11):1162–71.10.1002/gps.4183
Akbarian, S, Beeri, MS, Haroutunian, V. Epigenetic determinants of healthy and diseased brain aging and cognition. JAMA Neurol. 2013;70(6):711–8.
Ashish, N, Bhatt, P, Toga, AW. Global data sharing in Alzheimer disease research. Alzheimer Dis Assoc Disord. 2016;30(2):160–8.10.1097/WAD.0000000000000121